Primerry Raises Rs 7.1 Crore Pre-Seed to Build Pediatric Health Products

Getting a child to take medicine or sit still for a checkup is a small daily battle in households everywhere, and it is the problem Primerry has decided to build a company around. The Mumbai-based pediatric health-tech startup has closed a Rs 7.1 crore pre-seed round from a group of angel investors that includes well-known public-market investor Ashish Kacholia and Lashit Sanghvi.

Primerry was co-founded by Rushabh Nandu and Dr. Nihar Parekh, and the company is targeting children between the ages of two and fourteen with what it describes as modern, clinically credible, and easy-to-use healthcare products, an attempt to close the gap between generic over-the-counter offerings and products actually designed with a child's specific physiology and behavior in mind. The founding pair's pairing of a physician co-founder with a business-side operator is a common and generally sound structure for a healthcare startup, since it embeds clinical credibility directly into product decisions rather than bolting it on later through an advisory board.

Where the New Capital Is Actually Going

The company plans to roll out eight initial products priced between Rs 499 and Rs 1,499, a price band aimed squarely at India's growing middle-class consumer health spending rather than premium imported alternatives. Alongside the initial product line, Primerry is launching PocDoc, a customizable carrying case designed to make healthcare more engaging for children. Distribution will run across the company's own direct-to-consumer platform, quick-commerce apps, pharmacies, and specialty retail stores, a multi-channel approach that has become close to standard for Indian consumer health brands. The round's capital will go toward expanding the founding team, increasing research and development spend, and funding the initial product rollout.

Why an Overlooked Category Drew Experienced Angels

Pediatric health as a specific sub-category within India's broader consumer health boom has drawn less venture attention than categories like women's health or elder care, despite a large and growing addressable market of parents willing to spend on trusted children's health products. Angel investors like Kacholia, who has built a public reputation primarily around public-market investing rather than early-stage venture, participating directly in a pre-seed consumer health round is itself a modest signal that experienced capital allocators see enough of a market opportunity here to write a personal check well before institutional venture funds typically get involved.

What This Means for Founders

For a company at this stage, the real test will come after the initial eight products launch: whether parents treat Primerry as a trusted ongoing brand worth repeat purchases, or as a one-off purchase driven by novelty. A founder building in an overlooked consumer health sub-category should treat Primerry's approach, pairing clinical credibility with a low, accessible price band, as a reference point for proving out a large addressable market before it becomes obvious to institutional investors.

Browse the healthtech investor directory and consumer investor directory for active funds in Indian consumer health, read the baseline mechanics of a pre-seed round if the term is new, or explore active capital on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai